252 related articles for article (PubMed ID: 19003741)
1. Design and rationale of a randomized, double-blind, placebo-controlled phase III study for autologous bone marrow cell transplantation in critical limb ischemia: the BONe Marrow Outcomes Trial in Critical Limb Ischemia (BONMOT-CLI).
Amann B; Lüdemann C; Rückert R; Lawall H; Liesenfeld B; Schneider M; Schmidt-Lucke J
Vasa; 2008 Nov; 37(4):319-25. PubMed ID: 19003741
[TBL] [Abstract][Full Text] [Related]
2. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia.
Powell RJ; Comerota AJ; Berceli SA; Guzman R; Henry TD; Tzeng E; Velazquez O; Marston WA; Bartel RL; Longcore A; Stern T; Watling S
J Vasc Surg; 2011 Oct; 54(4):1032-41. PubMed ID: 21684715
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of the MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia in Subjects with Severe Peripheral Arterial Disease (MOBILE) trial investigating autologous bone marrow cell therapy for critical limb ischemia.
Wang SK; Green LA; Motaganahalli RL; Wilson MG; Fajardo A; Murphy MP
J Vasc Surg; 2017 Jun; 65(6):1850-1857.e2. PubMed ID: 28390770
[TBL] [Abstract][Full Text] [Related]
4. Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia.
Iafrati MD; Hallett JW; Geils G; Pearl G; Lumsden A; Peden E; Bandyk D; Vijayaraghava KS; Radhakrishnan R; Ascher E; Hingorani A; Roddy S
J Vasc Surg; 2011 Dec; 54(6):1650-8. PubMed ID: 22019148
[TBL] [Abstract][Full Text] [Related]
5. Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease.
Amann B; Luedemann C; Ratei R; Schmidt-Lucke JA
Cell Transplant; 2009; 18(3):371-80. PubMed ID: 19500466
[TBL] [Abstract][Full Text] [Related]
6. Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Therapeutic Efficacy of Angiogenesis Induced by Intraarterial Autologous Bone Marrow-Derived Stem Cells in Patients with Severe Peripheral Arterial Disease.
Sharma S; Pandey NN; Sinha M; Kumar S; Jagia P; Gulati GS; Gond K; Mohanty S; Bhargava B
J Vasc Interv Radiol; 2021 Feb; 32(2):157-163. PubMed ID: 33248918
[TBL] [Abstract][Full Text] [Related]
7. Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ischemia: the randomized, double-blind, placebo-controlled Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) trial.
Teraa M; Sprengers RW; Schutgens RE; Slaper-Cortenbach IC; van der Graaf Y; Algra A; van der Tweel I; Doevendans PA; Mali WP; Moll FL; Verhaar MC
Circulation; 2015 Mar; 131(10):851-60. PubMed ID: 25567765
[TBL] [Abstract][Full Text] [Related]
8. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia.
Losordo DW; Kibbe MR; Mendelsohn F; Marston W; Driver VR; Sharafuddin M; Teodorescu V; Wiechmann BN; Thompson C; Kraiss L; Carman T; Dohad S; Huang P; Junge CE; Story K; Weistroffer T; Thorne TM; Millay M; Runyon JP; Schainfeld R;
Circ Cardiovasc Interv; 2012 Dec; 5(6):821-30. PubMed ID: 23192920
[TBL] [Abstract][Full Text] [Related]
9. Ethnic minorities with critical limb ischemia derive equal amputation risk reduction from autologous cell therapy compared with whites.
Wang SK; Green LA; Gutwein AR; Drucker NA; Babbey CM; Gupta AK; Fajardo A; Motaganahalli RL; Wilson MG; Murphy MP
J Vasc Surg; 2018 Aug; 68(2):560-566. PubMed ID: 29503004
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the SAIL trial for intramuscular injection of allogeneic mesenchymal stromal cells in no-option critical limb ischemia.
Wijnand JGJ; Teraa M; Gremmels H; van Rhijn-Brouwer FCC; de Borst GJ; Verhaar MC;
J Vasc Surg; 2018 Feb; 67(2):656-661. PubMed ID: 29242062
[TBL] [Abstract][Full Text] [Related]
11. Autologous intra-arterial infusion of bone marrow mononuclear cells in patients with critical leg ischemia.
Chochola M; Pytlík R; Kobylka P; Skalická L; Kideryová L; Beran S; Varejka P; Jirát S; Køivánek J; Aschermann M; Linhart A
Int Angiol; 2008 Aug; 27(4):281-90. PubMed ID: 18677289
[TBL] [Abstract][Full Text] [Related]
12. Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal.
Lawall H; Bramlage P; Amann B
Thromb Haemost; 2010 Apr; 103(4):696-709. PubMed ID: 20174766
[TBL] [Abstract][Full Text] [Related]
13. Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia.
Murphy MP; Lawson JH; Rapp BM; Dalsing MC; Klein J; Wilson MG; Hutchins GD; March KL
J Vasc Surg; 2011 Jun; 53(6):1565-74.e1. PubMed ID: 21514773
[TBL] [Abstract][Full Text] [Related]
14. Autologous Bone Marrow Mononuclear Cell Implantation and Its Impact on the Outcome of Patients With Critical Limb Ischemia - Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
Pignon B; Sevestre MA; Kanagaratnam L; Pernod G; Stephan D; Emmerich J; Clement C; Sarlon G; Boulon C; Tournois C; Nguyen P
Circ J; 2017 Oct; 81(11):1713-1720. PubMed ID: 28603176
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of the JUVENTAS trial for repeated intra-arterial infusion of autologous bone marrow-derived mononuclear cells in patients with critical limb ischemia.
Sprengers RW; Moll FL; Teraa M; Verhaar MC;
J Vasc Surg; 2010 Jun; 51(6):1564-8. PubMed ID: 20488328
[TBL] [Abstract][Full Text] [Related]
16. Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients.
Abdul Wahid SF; Ismail NA; Wan Jamaludin WF; Muhamad NA; Abdul Hamid MKA; Harunarashid H; Lai NM
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010747. PubMed ID: 30155883
[TBL] [Abstract][Full Text] [Related]
17. Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials.
Teraa M; Sprengers RW; van der Graaf Y; Peters CE; Moll FL; Verhaar MC
Ann Surg; 2013 Dec; 258(6):922-9. PubMed ID: 23426345
[TBL] [Abstract][Full Text] [Related]
18. A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia.
Perin EC; Silva G; Gahremanpour A; Canales J; Zheng Y; Cabreira-Hansen MG; Mendelsohn F; Chronos N; Haley R; Willerson JT; Annex BH
Catheter Cardiovasc Interv; 2011 Dec; 78(7):1060-7. PubMed ID: 21594960
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of responders to autologous bone marrow cell therapy for no-option critical limb ischemia.
Madaric J; Klepanec A; Valachovicova M; Mistrik M; Bucova M; Olejarova I; Necpal R; Madaricova T; Paulis L; Vulev I
Stem Cell Res Ther; 2016 Aug; 7(1):116. PubMed ID: 27530339
[TBL] [Abstract][Full Text] [Related]
20. Autologous bone marrow mononuclear cell therapy for critical limb ischemia is effective and durable.
Liang TW; Jester A; Motaganahalli RL; Wilson MG; G'Sell P; Akingba GA; Fajardo A; Murphy MP
J Vasc Surg; 2016 Jun; 63(6):1541-5. PubMed ID: 27021379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
